Exact Sciences (EXAS) Rose Following the Acquisition Announcement by Abbott

2 hours ago 1

Soumya Eswaran

Tue, January 20, 2026 astatine 7:47 AM CST 3 min read

Fred Alger Management, an concern absorption company, released its “Alger Small Cap Focus Fund” fourth-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The US equity marketplace ended the 4th fourth connected a beardown note, with the S&P surging 2.7%, maintaining its dependable upward momentum. Investors' optimism was supported by better-than-expected firm earnings, the US Federal Reserve’s further involvement complaint easing stance, and a resilient macroeconomic backdrop. Improving clarity connected commercialized argumentation provided further support. Meanwhile, the 4th was characterized by expanding divergence beneath the scale level surface. The enthusiasm for AI concern is facing increasing doubts owed to bottlenecks, financing challenges, and uncertainty implicit its quality to make returns. The steadfast continues to observe secular trends that contiguous charismatic concern opportunities for small-cap stocks. In Q4 2025, Class A shares of the Fund outperformed the Russell 2000 Growth Index. The Utilities and Financials sectors contributed to the comparative show of the Fund successful the quarter, portion the Consumer Discretionary and Information Technology sectors detracted from performance. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its fourth-quarter 2025 capitalist letter, Alger Small Cap Focus Fund highlighted stocks specified arsenic Exact Sciences Corporation (NASDAQ:EXAS). Exact Sciences Corporation (NASDAQ:EXAS) provides crab screening and diagnostic trial products. On January 16, 2026, Exact Sciences Corporation (NASDAQ:EXAS) banal closed astatine $102.43 per share. One-month instrumentality of Exact Sciences Corporation (NASDAQ:EXAS) was 0.60%, and its shares gained 97.97% of their worth implicit the past 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a marketplace capitalization of $19.453 billion.

Alger Small Cap Focus Fund stated the pursuing regarding Exact Sciences Corporation (NASDAQ:EXAS) successful its 4th fourth 2025 capitalist letter:

"Exact Sciences Corporation (NASDAQ:EXAS) is simply a molecular diagnostics institution focused connected oncology testing, champion known for its Cologuard noninvasive colorectal crab screening franchise, alongside a broader portfolio and pipeline that includes molecular residual illness (MRD) and multi-cancer aboriginal detection (MCED) investigating initiatives. Shares contributed positively during the 4th aft Abbott announced a definitive all-cash statement to get Exact Sciences for astir $21 cardinal successful equity value, reflecting a meaningful premium and driving the banal higher."